{"id":"NCT01155661","sponsor":"Eli Lilly and Company","briefTitle":"A Safety Study in Participants With Major Depressive Disorder","officialTitle":"Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2010-07-02","resultsPosted":"2018-04-17","lastUpdate":"2018-04-17"},"enrollment":608,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Major"],"interventions":[{"type":"DRUG","name":"LY2216684 (edivoxetine)","otherNames":["LY2216684","edivoxetine"]},{"type":"DRUG","name":"SSRI","otherNames":["Selective Serotonin Reuptake Inhibitor"]}],"arms":[{"label":"LY2216684 (edivoxetine) + SSRI","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin reuptake inhibitor (SSRI) for up to approximately 1 year in participants with major depressive disorder (MDD) who are partial responders to their SSRI treatment.","primaryOutcome":{"measure":"The Number of Participants Experiencing Clinically Significant Effects","timeFrame":"Baseline through 54 weeks","effectByArm":[{"arm":"LY2216684 + SSRI","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":6},"locations":{"siteCount":48,"countries":["United States","Brazil","Chile","Lithuania","Mexico","Netherlands","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":600},"commonTop":["Headache","Nausea","Hyperhidrosis","Constipation","Dizziness"]}}